Panntherapi

Panntherapi is a clinical stage deeptech biotech company which develops innovative drugs for chronic neurological diseases by acting on a new mechanism only activated under pathological conditions, allowing a better efficacy and a higher safety. 

Our first product is at clinical stage to treat an orphan highly resistant epilepsy: using post operative brain tissues from patients, still alive and having seizure ex vivo, our drug fully stops seizures in >80% of cases with no impact on other brain functions, on the contrary of current anti-epileptic drugs having a lot of side effects. Other candidates were identified to stop crisis in multiple sclerosis, chronic pain or psychiatric disorders.

Laureate of the EIC Accelerator, i-Lab and other prizes, we are looking for a lead investor for our 20M€ Series A, being able to provide more than 70% of the amount (EU VC, Family Office, EIC equity)